Guarino Maria, Cossiga Valentina, Capasso Mario, Mazzarelli Chiara, Pelizzaro Filippo, Sacco Rodolfo, Russo Francesco Paolo, Vitale Alessandro, Trevisani Franco, Cabibbo Giuseppe
Gastroenterology and Hepatology Unit, Department of Clinical Medicine and Surgery, University of Naples "Federico II", 80138 Naples, Italy.
Hepatology and Gastroenterology Unit, ASST Grande Ospedale Metropolitano Niguarda, 20162 Milan, Italy.
J Clin Med. 2022 Jul 31;11(15):4475. doi: 10.3390/jcm11154475.
Worldwide, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) significantly increases mortality and morbidity. The Coronavirus Disease 2019 (COVID-19) outbreak has had a considerable impact on healthcare systems all around the world, having a significant effect on planned patient activity and established care pathways, in order to meet the difficult task of the global pandemic. Patients with hepatocellular carcinoma (HCC) are considered a particularly susceptible population and conceivably at increased risk for severe COVID-19 because of two combined risk factors: chronic advanced liver disease and HCC itself. In these challenging times, it is mandatory to reshape clinical practice in a prompt way to preserve the highest standards of patient care and safety. However, due to the stay-at-home measures instituted to stop the spread of COVID-19, HCC surveillance has incurred a dramatic drop, and care for HCC patients has been rearranged by refining the algorithm for HCC treatment to the COVID-19 pandemic, permitting these patients to be safely managed by identifying those most at risk of neoplastic disease progression.
在全球范围内，严重急性呼吸综合征冠状病毒2（SARS-CoV-2）显著增加了死亡率和发病率。2019冠状病毒病（COVID-19）疫情对世界各地的医疗系统产生了相当大的影响，对计划中的患者活动和既定的护理途径产生了重大影响，以应对全球大流行这一艰巨任务。肝细胞癌（HCC）患者被认为是特别易感人群，由于慢性晚期肝病和HCC本身这两个综合风险因素，他们感染重症COVID-19的风险可能增加。在这些充满挑战的时期，必须迅速重塑临床实践，以保持最高的患者护理和安全标准。然而，由于为阻止COVID-19传播而实施的居家措施，HCC监测大幅下降，并且通过完善针对COVID-19大流行的HCC治疗算法，重新安排了对HCC患者的护理，通过识别那些肿瘤疾病进展风险最高的患者，使这些患者能够得到安全管理。
